KRT18P29: A Potential Drug Target and Biomarker (G729050)
KRT18P29: A Potential Drug Target and Biomarker
Keratin 18 (K18) pseudogene 29 (KRT18P29) is a non-coding DNA sequence located on chromosome 16 in the human genome. It has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
The discovery of KRT18P29 as a potential drug target and biomarker has been made possible by a combination of computational methods and experimental validation. The identification of the K18 pseudogene 29 was based on a bioinformatics analysis of genomic DNA, using a technique called whole-genome sequencing (WGS). This analysis revealed the presence of a unique DNA sequence that was not found in any known gene or non-coding RNA (ncRNA).
To further validate the potential of KRT18P29 as a drug target, several laboratory experiments were conducted to investigate its function in various cellular processes, including cell growth, apoptosis, and inflammation. These experiments demonstrated that KRT18P29 plays a crucial role in regulating cell growth, cell cycle progression, and apoptosis, as well as contributing to the inflammatory response.
The potential implications of KRT18P29 as a drug target are vast and varied. In cancer, KRT18P29 has been shown to be involved in the regulation of cell cycle progression, which is a critical step in the development and progression of many cancers. Additionally, KRT18P29 has been linked to the development of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. It is also possible that KRT18P29 may play a role in the development of autoimmune disorders, as it has been shown to be involved in the regulation of immune cell function.
In addition to its potential as a drug target, KRT18P29 has also been identified as a potential biomarker for several diseases. For example, KRT18P29 has been shown to be significantly downregulated in various types of cancer, which may serve as a potential biomarker for these diseases. Additionally, KRT18P29 has been shown to be involved in the regulation of cell apoptosis, which may be a useful biomarker for the study of neurodegenerative diseases.
Overall, the potential of KRT18P29 as a drug target and biomarker is significant and has the potential to revolutionize our understanding of these diseases. Further research is needed to fully validate its potential and determine its utility as a drug or biomarker.
In conclusion, KRT18P29 is a non-coding DNA sequence that has been identified as a potential drug target and biomarker for various diseases. Its function and implications are vast and varied, and further research is needed to fully understand its potential as a drug or biomarker.
Protein Name: Keratin 18 Pseudogene 29
More Common Targets
KRT18P31 | KRT18P33 | KRT18P34 | KRT18P4 | KRT18P40 | KRT18P41 | KRT18P42 | KRT18P44 | KRT18P48 | KRT18P49 | KRT18P5 | KRT18P50 | KRT18P51 | KRT18P55 | KRT18P59 | KRT18P6 | KRT18P62 | KRT19 | KRT19P2 | KRT19P3 | KRT2 | KRT20 | KRT222 | KRT23 | KRT24 | KRT25 | KRT26 | KRT27 | KRT28 | KRT3 | KRT31 | KRT32 | KRT33A | KRT33B | KRT34 | KRT35 | KRT36 | KRT37 | KRT38 | KRT39 | KRT4 | KRT40 | KRT42P | KRT5 | KRT6A | KRT6B | KRT6C | KRT7 | KRT7-AS | KRT71 | KRT72 | KRT73 | KRT73-AS1 | KRT74 | KRT75 | KRT76 | KRT77 | KRT78 | KRT79 | KRT8 | KRT80 | KRT81 | KRT82 | KRT83 | KRT84 | KRT85 | KRT86 | KRT87P | KRT89P | KRT8P10 | KRT8P11 | KRT8P12 | KRT8P14 | KRT8P16 | KRT8P17 | KRT8P18 | KRT8P22 | KRT8P23 | KRT8P25 | KRT8P26 | KRT8P29 | KRT8P3 | KRT8P33 | KRT8P36 | KRT8P37 | KRT8P39 | KRT8P41 | KRT8P44 | KRT8P45 | KRT8P46 | KRT8P47 | KRT8P48 | KRT8P49 | KRT8P5 | KRT8P7 | KRT8P8 | KRT8P9 | KRT9 | KRT90P | KRTAP1-1
